- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Regenxbio, Solid report data with Duchenne gene therapies | ||
| Fr | NHS hospitals 'should resist Palantir software rollout' | ||
| Fr | Immutep investors spooked by LAG-3 failure in lung cancer | ||
| Fr | Poll finds Americans cutting back elsewhere to fund health | ||
| Do | Iran hackers claim cyberattack at US medtech firm | ||
| Do | Ipsen appoints Michelle Werner as North America head | ||
| Do | Evotec slashes staff as turnaround plan gathers pace | ||
| Do | Eisai joins with Pokémon for sleep awareness drive | ||
| Do | NVIDIA sinks $2bn into AI cloud provider Nebius | ||
| Mi | Novo rapped by FDA for not reporting drug adverse effects | ||
| Mi | NHS cleared to use Astellas' non-hormonal menopause drug | ||
| Mi | Vertex preps FDA filing for IgAN drug after phase 3 readout | ||
| Mi | NICE says no to Genmab cervical cancer therapy | ||
| Mi | Veeva buys brand engagement firm Ostro for $100m | ||
| Di | FDA approves leucovorin - but not for autism | ||
| Di | FDA cuts testing requirements for biosimilars once again | ||
| Di | BioNTech bigwigs will step down to form new mRNA company | ||
| Di | Lundbeck names AI head in quest to become 'bionic' company | ||
| Di | BMS eyes another celmod filing in myeloma after phase 3 win | ||
| 09.03. | Novo partners with Hims & Hers again, ending GLP-1 spat | ||
| 09.03. | Incyte breaks new ground in anal cancer with EU approval | ||
| 09.03. | Alfasigma licenses liver drug from GSK in $590m deal | ||
| 09.03. | Roche's oral SERD flunks phase 3 breast cancer test | ||
| 09.03. | Safety concerns prompt Ipsen to pull Tazverik from market | ||
| 06.03. | Servier snaps up cancer biotech Day One in $2.5bn deal |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.